Summary: A Phase 2 randomized clinical trial demonstrates that a single 25 mg dose of psilocybin, combined with psychotherapeutic support, provides rapid, statistically significant, and clinically meaningful reduction in symptoms of common, recurrent depression.
The study showed that an...